Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGT-181 Extension Study in Adult MPS I
NCT02597114Phase 1Completed
- Sponsor
- ArmaGen
- Start
- Nov 2015
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
Phase 1, open-label, single-arm trial of valanafusp alpha in mucopolysaccharidosis type I, sponsored by ArmaGen. Primary endpoint: Number of participants with adverse events as a measure of safety and tolerability at 104 weeks. Started Nov 2015; status: completed.
02
Drugs
valanafusp alpha
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on NCT02597114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597114.